CC BY-NC 4.0 · Arch Plast Surg 2018; 45(06): 600-601
DOI: 10.5999/aps.2017.01214
Image

Epithelial-mesenchymal transition in keloid tissue

Chae-Eun Yang
Department of Plastic and Reconstructive Surgery, Institute for Human Tissue Restoration, Yonsei University College of Medicine, Seoul, Korea
,
Seung Jin Moon
Department of Plastic and Reconstructive Surgery, Institute for Human Tissue Restoration, Yonsei University College of Medicine, Seoul, Korea
,
Soo Jung Kim
Department of Plastic and Reconstructive Surgery, Institute for Human Tissue Restoration, Yonsei University College of Medicine, Seoul, Korea
,
Ju Hee Lee
Department of Dermatology and Cutaneous Biology Research Institute, Yonsei University College of Medicine, Seoul, Korea
,
Chae-Ok Yun
Department of Bioengineering, Hanyang University College of Engineering, Seoul, Korea
,
Dae Hyun Lew
Department of Plastic and Reconstructive Surgery, Institute for Human Tissue Restoration, Yonsei University College of Medicine, Seoul, Korea
,
Won Jai Lee
Department of Plastic and Reconstructive Surgery, Institute for Human Tissue Restoration, Yonsei University College of Medicine, Seoul, Korea
› Author Affiliations

Fibroblasts at the wound site are recognized as the primary drivers of scar formation. They differentiate into myofibroblasts, the key mediators of fibrosis, which are responsible for collagen deposition and wound contraction. Repair processes cease when epithelialization is completed in normal wounds, whereas in keloid wounds, they may continue and result in excessive accumulation of unorganized extracellular matrix, forming problematic scars.

In addition to resident mesenchymal cells, fibroblasts and myofibroblasts are thought to be derived from multiple sources, including epithelial-mesenchymal transition (EMT) [1]. During this process, epithelial cells experience intercellular and intracellular changes, including dissociation of junctional complexes, loss of apical-basolateral polarity, and repression of epithelial markers. As a result, epithelial cells lose many of their properties and take on characteristics of mesenchymal cells.

To investigate this process, an immunofluorescence assay using both epithelial and mesenchymal markers was performed using keloid tissues obtained from the anterior chest wall of a 70-year-old male patient ([Fig. 1]). After fixation, cells were incubated with primary antibodies against E-cadherin and vimentin (Abcam, Cambridge, UK), and subsequently labelled with fluorescently-tagged secondary antibodies. Counterstaining with 4’,6-diamidino-2-phenylindole (DAPI) (VECTOR Laboratories, Burlingame, CA, USA) was also performed.

Zoom Image
Fig. 1. Patient with a keloid. A 70-year-old male with a keloid on the post-sternotomy area suffered from itchiness, pain, and skin tightening. The keloid was surgically excised intralesionally.

Cells were visualized using an LSM 700 Carl Zeiss confocal microscope (Carl Zeiss MicroImaging, Thornwood, NY, USA). E-cadherin and vimentin expression were simultaneously observed at the dermo-epidermal junction in keloid tissue, indicating the occurrence of EMT ([Fig. 2]).

Zoom Image
Fig. 2. Epithelial-mesenchymal transition (EMT) characteristics in keloid tissue. (A) Expression of the epithelial marker E-cadherin (green) and (B) the mesenchymal marker vimentin (red) was observed via immunofluorescence. (C) DAPI counterstain of nuclei (blue). (D) Co-expression of E-cadherin and vimentin at the dermo-epidermal junction was observed, indicating the occurrence of the EMT process (A-D, magnification ×630).

Although further investigations with additional keloid specimens are needed, we hope that our study yields some insight into the mechanisms of keloid formation.



Publication History

Received: 25 July 2017

Accepted: 15 March 2018

Article published online:
03 April 2022

© 2018. The Korean Society of Plastic and Reconstructive Surgeons. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonCommercial License, permitting unrestricted noncommercial use, distribution, and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes. (https://creativecommons.org/licenses/by-nc/4.0/)

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA